In vitro drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

References

• Becker MA, Schumacher HR, Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine 2005; 353: 2450–2461
   PubMed Web of Science ®Google Scholar
• Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527–537
   PubMedGoogle Scholar
• Ciotti M, Chen F, Rubaltelli FF, Owens IS. Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler–Najjar type I disease. Biochimica et Biophysica Acta 1998; 1407: 40–50
   PubMed Web of Science ®Google Scholar
• Dalén P, Dahl M-L, Eichelbaum M, Bertilsson L, Wilkinson GR. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9: 697–706
   PubMedGoogle Scholar
• Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193–201
   PubMedGoogle Scholar
• Fehske KJ, Muller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochemical Pharmacology 1981; 30: 687–692
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews 2001; 33: 273–297
   PubMed Web of Science ®Google Scholar
• Grabowski BA, Khosravan R, Wu JT, Lademacher C, Vernillet L. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthritis and Rheumatism 2005; 52(9 Suppl)S103–104
   Google Scholar
• Hirano K, Watanabe Y, Adachi T, Ito Y, Sugiura M. Drug-binding properties of human α-foetoprotein. Biochemical journal 1985; 231: 189–191
   PubMed Web of Science ®Google Scholar
• Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, Komoriya K. Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Science 2000; 66: 2051–2070
   PubMed Web of Science ®Google Scholar
• Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in human. Drug Metabolism Reviews 2000; 32(Suppl. 2)269
   Google Scholar
• Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clinical Pharmacology and Therapeutics 1996; 59: 647–653
   PubMed Web of Science ®Google Scholar
• Khosravan R, Erdman K, Vernillet L, Wu JT, Joseph-Ridge N, Umeda S, Mulford D. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects. Clinical Pharmacology and Therapeutics 2005a; 77: 43
   PubMed Web of Science ®Google Scholar
• Khosravan R, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthritis and Rheumatism 2005c; 52(Suppl. 9)S102–S103
   Google Scholar
• Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. Journal of Clinical Pharmacology 2006; 46: 855–866
   PubMed Web of Science ®Google Scholar
• Khosravan R, Wu JT, Lademacher C, Grabowski BA, Vernillet L. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin. Journal of Clinical Pharmacology 2005b; 45: 1084
   Web of Science ®Google Scholar
• Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide, and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 71–80
   PubMedGoogle Scholar
• Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides, Nucleotides, Nucleic Acids 2004; 23: 1119–1122
   PubMed Web of Science ®Google Scholar
• Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, Echizen H, Ishizaki T. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 860–867
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255–269
   PubMedGoogle Scholar
• Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of Febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American Journal of Therapeutics 2005; 12: 22–34
   PubMedGoogle Scholar
• McGowan FX, Reiter MJ, Pritchett ELC, Shand DG. Verapamil plasma binding: Relationship to α1-acid glycoprotein and drug efficacy. Clinical Pharmacology and Therapeutics 1983; 33: 485–490
   PubMed Web of Science ®Google Scholar
• Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Journal of Biological Chemistry 2003; 278: 1848–1855
   PubMed Web of Science ®Google Scholar
• Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. European Journal of Pharmacology 1993; 241: 183–188
   PubMed Web of Science ®Google Scholar
• Sjöholm I, Ekman B, Kober A, Ljungstedt-Påhlman I, Seiving B, Sjödin T. Binding of drug to human serum albumin: XI. Molecular Pharmacology 1979; 16: 767–777
   PubMed Web of Science ®Google Scholar
• Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Molecular Pharmacology 1976; 12: 1056–1061
   Web of Science ®Google Scholar
• Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8: 365–373
   PubMedGoogle Scholar
• Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Science 2005; 76: 1835–1847
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology 2000; 40: 581–616
   PubMed Web of Science ®Google Scholar
• Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clinical Pharmacology and Therapeutics 1979; 26: 584–591
   PubMed Web of Science ®Google Scholar